Dr. Aman Chauhan, MD
Claim this profileUniversity of Kentucky/Markey Cancer Center
Area of expertise
Neuroendocrine Tumors
Aman Chauhan, MD has run 7 trials for Neuroendocrine Tumors. Some of their research focus areas include:
Carcinoid Tumor
Aman Chauhan, MD has run 6 trials for Carcinoid Tumor. Some of their research focus areas include:
Affiliated Hospitals
University Of Kentucky/Markey Cancer Center
University Of Miami Miller School Of Medicine-Sylvester Cancer Center
Clinical Trials Aman Chauhan, MD is currently running
Radioactive Drug vs Everolimus
for Neuroendocrine Cancer
This phase II trial compares the effect of retreatment with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) to the usual approach of treatment with everolimus, sunitinib, or cabozantinib in patients who have previously received 177Lu-DOTATATE for gastroenteropancreatic neuroendocrine tumor (GEPNET) that has spread from where it first started (primary site) to other places in the body (metastatic) and that cannot be removed by surgery (unresectable). PRRT is a type of radiation therapy for which a radioactive chemical is linked to a peptide (small protein) that targets tumor cells. When this radioactive peptide is injected into the body, it binds to a specific receptor found on some tumor cells. The radioactive peptide builds up in these cells and helps kill the tumor cells without harming normal cells. In this trial 177Lu-DOTATATE is used for PRRT. 177Lu-DOTATATE PRRT may increase the length of time until worsening of the GEPNET compared to the usual approach. Everolimus is in a class of medications called kinase inhibitors. It is also a type of angiogenesis inhibitor. Everolimus works by stopping tumor cells from reproducing and by decreasing blood supply to the tumor cells. Sunitinib and cabozantinib, block certain proteins, which may help keep tumor cells from growing. They may also prevent the growth of new blood vessels that tumors need to grow. Sunitinib malate is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Retreating with 177Lu-DOTATATE may work better than everolimus, sunitinib or cabozantinib in shrinking or stabilizing tumors in patients with metastatic and unresectable GEPNET who were previously treated with 177Lu-DOTATATE.
Recruiting
1 award
Phase 2
Lutetium Lu 177 Dotatate
for Lung Carcinoid Tumor
This trial studies the effect of lutetium Lu 177 dotatate in patients with advanced bronchial neuroendocrine tumors. Lutetium Lu 177 dotatate targets cancer cells with radiation, aiming to kill or shrink them while sparing healthy cells. The goal is to see if it works better than the usual treatment. Everolimus has been shown to help patients with various types of neuroendocrine tumors.
Recruiting
1 award
Phase 2
10 criteria
More about Aman Chauhan, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Aman Chauhan, MD has experience with
- Lutetium Lu 177 Dotatate
- Nivolumab
- Triapine
- Everolimus
- Cabozantinib
- Ipilimumab
Breakdown of trials Aman Chauhan, MD has run
Neuroendocrine Tumors
Carcinoid Tumor
Cancer
Neuroendocrine Carcinoma
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aman Chauhan, MD specialize in?
Aman Chauhan, MD focuses on Neuroendocrine Tumors and Carcinoid Tumor. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Aman Chauhan, MD currently recruiting for clinical trials?
Yes, Aman Chauhan, MD is currently recruiting for 2 clinical trials in Lexington Kentucky. If you're interested in participating, you should apply.
Are there any treatments that Aman Chauhan, MD has studied deeply?
Yes, Aman Chauhan, MD has studied treatments such as Lutetium Lu 177 Dotatate, Nivolumab, Triapine.
What is the best way to schedule an appointment with Aman Chauhan, MD?
Apply for one of the trials that Aman Chauhan, MD is conducting.
What is the office address of Aman Chauhan, MD?
The office of Aman Chauhan, MD is located at: University of Kentucky/Markey Cancer Center, Lexington, Kentucky 40536 United States. This is the address for their practice at the University of Kentucky/Markey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.